Along with the evaluation of strategic alternatives, Eyenovia continues to progress development of its advanced Optejet device and is exploring options for use as both a consumer "user-filled" product and a proprietary drug-device combination. The user-filled product would advance through a device regulatory pathway without the need for clinical trials and could be commercially available by the end of this year.